CompletedPhase 1NCT01564225
A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200
Studying Ectodermal dysplasia syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Edimer Pharmaceuticals
- Principal Investigator
- Ophir Klein, MD, PhDUniversity of California, San Francisco
- Intervention
- EDI200(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 18-40 years · All sexes
- Timeline
- 2012 – 2013
Study locations (2)
- University of California, San Francisco, San Francisco, California, United States
- Community Research, Cincinnati, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01564225 on ClinicalTrials.govOther trials for Ectodermal dysplasia syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07468019Organization's Unique Protocol IDCairo University
- ACTIVE NOT RECRUITINGNCT07096206Characteristics and Impacts of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in Boys: An Observational International StudyPierre Fabre Medicament
- RECRUITINGPHASE2NCT04980638Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal DysplasiaEspeRare Foundation